{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:32:21Z","timestamp":1767987141177,"version":"3.49.0"},"reference-count":15,"publisher":"The Japan Society of Coloproctology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Anus Rectum Colon"],"published-print":{"date-parts":[[2025,10,25]]},"DOI":"10.23922\/jarc.2025-031","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T22:08:13Z","timestamp":1761343693000},"page":"465-471","source":"Crossref","is-referenced-by-count":1,"title":["Ophthalmic Toxicities in BEACON Triplet Therapy for BRAF V600E-Mutant Colorectal Cancer: A Case Series"],"prefix":"10.23922","volume":"9","author":[{"given":"Hayato","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Surgery, Shizuoka Saiseikai General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Suzumura","sequence":"additional","affiliation":[{"name":"Department of Surgery, Shizuoka Saiseikai General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Oiwa","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shizuoka Saiseikai General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Surgery, Shizuoka Saiseikai General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Nishimae","sequence":"additional","affiliation":[{"name":"Department of Surgery, Shizuoka Saiseikai General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Surgery, Shizuoka Saiseikai General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Terasaki","sequence":"additional","affiliation":[{"name":"Department of Surgery, Shizuoka Saiseikai General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshichika","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Surgery, Shizuoka Saiseikai General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10009","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019 Oct;381 (17):1632-43.","DOI":"10.1056\/NEJMoa1908075"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yokota T, Ura T, Shibata N, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011 Mar;104 (5):856-62.","DOI":"10.1038\/bjc.2011.19"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Phipps AI, Buchanan DD, Makar KW, et al. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2012 Oct;21 (10):1792-8.","DOI":"10.1158\/1055-9965.EPI-12-0674"},{"key":"4","unstructured":"4. Japanese Society for Cancer of the Colon and Rectum. Japanese guidelines for the treatment of colorectal cancer 2024. Tokyo: Japanese Society for Cancer of the Colon and Rectum; 2024. Chapter 5; p. 39-53."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. M\u00e9ndez-Mart\u00ednez S, Calvo P, Ruiz-Moreno O, et al. Ocular adverse events associated with MEK inhibitors. Retina. 2019 Aug;39 (8):1435-50.","DOI":"10.1097\/IAE.0000000000002451"},{"key":"6","unstructured":"6. Ono Pharmaceutical Co., Ltd. Appropriate use guide for BRAFTOVI (encorafenib). 2023 [cited 2024 Aug 21]. Available from: https:\/\/www.ono-oncology.jp\/sites\/default\/files\/2024-06\/braftovi-rmp.pdf"},{"key":"7","unstructured":"7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002 Jun;417 (6892):949-54."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol. 2021 Feb;39 (4):273-84.","DOI":"10.1200\/JCO.20.02088"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19 (5):603-15.","DOI":"10.1016\/S1470-2045(18)30142-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Jiang Q, Cao C, Lu S, et al. MEK\/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells. Int J Mol Med. 2009 Jun;23 (6):771-7.","DOI":"10.3892\/ijmm_00000191"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sakata H, Murase M, Kato T, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: an early post-marketing phase vigilance study. Int J Clin Oncol. 2023 Jan;28 (1):139-44.","DOI":"10.1007\/s10147-022-02264-z"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Van Cutsem E, Taieb J, Yaeger R, et al. Anchor CRC: results from a single-arm, Phase II study of encorafenib plus binimetinib and cetuximab in previously untreated BRAFV600E-mutant metastatic colorectal cancer. J Clin Oncol. 2023 May;41 (14):2628-37.","DOI":"10.1200\/JCO.22.01693"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Urner-Bloch U, Urner M, Jaberg-Bentele N, et al. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: long-term ophthalmic effects. Eur J Cancer. 2016 Sep;65:130-8.","DOI":"10.1016\/j.ejca.2016.06.018"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Purbrick RM, Osunkunle OA, Talbot DC, et al. Ocular toxicity of mitogen-activated protein kinase inhibitors. JAMA Oncol. 2017 Feb;3:275-7.","DOI":"10.1001\/jamaoncol.2016.4213"},{"key":"15","unstructured":"15. Klein R, Klein BE, Moss SE, et al. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2009 Jan;98:133-41; discussion 141."}],"container-title":["Journal of the Anus, Rectum and Colon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jarc\/9\/4\/9_2025-031\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T04:36:32Z","timestamp":1761366992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jarc\/9\/4\/9_2025-031\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.23922\/jarc.2025-031","relation":{},"ISSN":["2432-3853"],"issn-type":[{"value":"2432-3853","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"article-number":"2025-031"}}